Skip to main content Accessibility help
×
Home

Vaccines for cervical cancer

  • C. M. LOWNDES (a1)

Summary

This review focuses on current and future prevention of invasive cervical cancer (ICC), the second most common cancer among women worldwide. Implementation of population-based cytological screening programmes, using the ‘Pap’ smear to detect pre-cancerous lesions in the cervix, has resulted in substantial declines in mortality and morbidity from ICC in North America and some European countries. However, cases of, and deaths from, ICC continue to occur. Primary prevention of infection with high-risk human papillomavirus (HPV) types, the central causal factor of ICC, could further reduce incidence of and mortality from ICC. This is particularly the case in developing countries, which bear 80% of the burden of ICC, and where effective Pap screening programmes are extremely difficult to implement. Very promising results from several trials of synthetic HPV type-specific monovalent (HPV 16) and bivalent (HPV 16 and 18) vaccines have recently been published, showing high efficacy against type-specific persistent HPV infection and development of type-specific pre-cancerous lesions. Large-scale phase III trials of a number of such vaccine candidates are currently underway, and there is real hope that an effective vaccine capable of protecting against infection with HPV types 16 and 18 (which together account for ∼70% of cervical cancer cases worldwide), and thereby of preventing development of a very significant proportion of cases of ICC, could be available within the next 2 years.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Vaccines for cervical cancer
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Vaccines for cervical cancer
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Vaccines for cervical cancer
      Available formats
      ×

Copyright

Corresponding author

Author for correspondence: C. M. Lowndes, Ph.D., Consultant Scientist (Epidemiology), Head, STI Section, Department of HIV and Sexually Transmitted Infections, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London, NW9 5EQ, UK. (Email: clowndes@uresp.ulaval.ca)

References

Hide All
Parkin, DM, Bray, FI, Devesa, SS. Cancer burden in the year 2000: the global picture. Eur J Cancer 2001; 37 (Suppl 8yes): S4S66.
Bosch, FX, Lorincz, A, Munoz, N, Meijer, CJ, Shah, KV.The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244265.
Ferlay, J, Bray, F, Pisani, P, Parkin, DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5, version 2.0. IARC Press, Lyon, 2004 (http://www-depdb.iarc.fr/globocan/GLOBOframe.htm). Accessed 2 July 2005.
Sanders, GD, Taira, AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9: 3748.
Kiviat, N, Koutsky, LA, Paavonen, J. Cervical neoplasia and other STD-related genital tract neoplasias. In: Holmes, KK, Sparling, PF, Mardh, P-A, Lemon, SM, Stamm, WE, Piot, P, Wasserheit, JN, eds. Sexually transmitted diseases, chapter 49. New York, McGraw-Hill, 1999: 669684.
Zheng, T, Holford, TR, Ma, Z, Chen, Y, Liu, W, Ward, BA, Boyle, P. The continuing increase in adenocarcinoma of the uterine cervix: a birth cohort phenomenon. Int J Epidemiol 1996; 25: 252258.
Sasieni, P, Adams, J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 2001; 357: 14901493.
Franco, EL, Duarte-Franco, E, Ferenczy, A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. Can Med Assoc J 2001; 164: 10171025.
Lehtinen, M, Paavonen, J. Efficacy of preventive human papillomavirus vaccination. Int J STD AIDS 2001; 12: 771776.
Gillison, ML, Shah, KV. Role of mucosal human papillomavirus in nongenital cancers. J Natl Cancer Inst Monogr 2003; 31: 5765.
Woodman, CB, Collins, S, Winter, H, et al. . Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357: 18311836.
Burk, RD, Kelly, P, Feldman, J, et al. . Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis 1996; 23: 333341.
Dillner, J, Kallings, I, Brihmer, C, et al. . Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 1996; 173: 13941398.
Koutsky, LA, Kiviat, NB. Genital human papillomaviruses. In: Holmes, KK, Sparling, PF, Mardh, P-A, Lemon, SM, Stamm, WE, Piot, P, Wasserheit, JN, eds. Sexually transmitted diseases, chapter 49. New York, McGraw-Hill, 1999: 669684.
Kjaer, SK, van den Brule, AJ, Paull, G, et al. . Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002; 325: 572.
Karlsson, R, Jonsson, M, Edlund, K, et al. . Lifetime number of partners as the only independent risk factor for human papillomavirus infection: a population-based study. Sex Transm Dis 1995; 22: 119127.
Ho, GY, Bierman, R, Beardsley, L, Chang, CJ, Burk, RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423428.
Franco, EL, Villa, LL, Sobrinho, JP, et al. . Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180: 14151423.
Herrero, R, Hildesheim, A, Bratti, C, et al. . Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000; 92: 464474.
Rousseau, MC, Villa, LL, Costa, MC, Abrahamowicz, M, Rohan, TE, Franco, E. Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities. Sex Transm Dis 2003; 30: 581587.
Elfgren, K, Kalantari, M, Moberger, B, Hagmar, B, Dillner, J. A population-based five-year follow-up study of cervical human papillomavirus infection. Am J Obstet Gynecol 2000; 183: 561567.
Galloway, DA. Papillomavirus vaccines in clinical trials. Lancet Infect Dis 2003; 3: 469475.
Ho, GY, Burk, RD, Klien, S, et al. . Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995; 87: 13651371.
Bosch, FX, Manos, MM, Munoz, N, et al. . Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 796802.
Munoz, N, Bosch, FX, de Sanjose, S, et al.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518527.
Lehtinen, M, Paavonen, J. Effectiveness of preventive human papillomavirus vaccination. Int J STD & AIDS 2003; 14: 787792.
Anttila, T, Saikku, P, Koskela, P, et al. . Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. J Am Med Assoc 2001; 285: 4751.
Smith, JS, Munoz, N, Herrero, R, et al. . Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis 2002; 185: 324331.
Lehtinen, M, Koskela, P, Jellum, E, et al. . Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case-control study in the Nordic countries. Am J Epidemiol 2002; 156: 687692.
Smith, JS, Herrero, R, Bosetti, C, et al. .; International Agency for Research on Cancer (IARC) Multicentric Cervical Cancer Study Group. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002; 94: 16041613.
Zenilman, JM. Chlamydia and cervical cancer: a real association? J Am Med Assoc 2001; 285: 8183.
Hemminki, K, Dong, C, Vaittinen, P. Familial risks in cervical cancer: is there a hereditary component? Int J Cancer 1999; 82: 775781.
Castellsague, X, Bosch, FX, Munoz, N, et al. .; International Agency for research on Cancer Multicenter Cervical Cancer Study Group. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002; 346: 11051112.
Solomon, D, Davey, D, Kurman, R, et al. .; Forum Group Members; Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. J Am Med Assoc 2002; 287: 21142119.
Gustafsson, L, Ponten, J, Zack, M, Adami, HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997; 8: 755763.
Levi, F, Lucchini, F, Negri, E, Franceschi, S, la Vecchia, C. Cervical cancer mortality in young women in Europe: patterns and trends. Eur J Cancer 2000; 36: 22662271.
Martin-Hirsch, PL, Koliopoulos, G, Paraskevaidis, E. Is it now time to evaluate the true accuracy of cervical cytology screening? A review of the literature. Eur J Gynaecol Oncol 2002; 23: 363365.
Hakama, M, Hristova, L. Effect of screening for cancer in the Nordic countries on deaths, costs and quality of life. Acta Oncol 1998; 36: 1160.
Peto, J, Gilham, C, Fletcher, O, Matthews, FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364: 249256.
Nanda, K, McCrory, DC, Myers, ER, et al. . Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000; 132: 810819.
Crum, CP. The beginning of the end for cervical cancer? N Engl J Med 2002; 347: 17031705.
European Commission DG V F.2. ‘Europe against cancer’ programme/Committee on quality assurance, training and education of the European Federation of Cytology Societies (QUATE). European guidelines for quality assurance in cervical cancer screening, CRSG, 1997 (Technical editor: Dr Chris de Woolf). (http://crsg.ubc.kun.nl/quate/Guidelines/euindex.html). Accessed 15 December 2002.
Laukkanen, P, Koskela, P, Pukkala, E, et al. . Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol 2003; 84: 21052109.
Goldie, SJ, Kuhn, L, Denny, L, Pollack, A, Wright, TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. J Am Med Assoc 2001; 285: 31073115.
Cuzick, J, Szarewski, A, Cubie, H, et al. . Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003; 362: 18711876.
Kulasingam, SL, Hughes, JP, Kiviat, NB, et al. . Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. J Am Med Assoc 2002; 288: 17491757.
Wright, TC Jr., Cox, JT, Massad, LS, Twiggs, LB, Wilkinson, EJ; ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. J Am Med Assoc 2002; 287: 21202129.
Peto, J, Gilham, C, Deacon, J, et al. . Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004; 91: 942953.
Koutsky, LA, Ault, KA, Wheeler, CM, et al. . A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 16451651.
Harper, DM, Franco, EL, Wheeler, C, et al. .; GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 17571765.
Lehtinen, M, Paavonen, J. Vaccination against human papillomaviruses shows great promise. Lancet 2004; 364: 17311732.
Schiller, JT, Davies, P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004; 2: 343347.
Villa, LL, Costa, RL, Petta, CA, et al. . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271278.
Davidson, EJ, Boswell, CM, Sehr, P, et al. . Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003; 63: 60326041.
Kirnbauer, R. Papillomavirus-like particles for serology and vaccine development. Intervirology 1996; 39: 5461.
Munoz, N, Bosch, FX, Castellsague, X, et al. . Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278285.
Liaw, KL, Hildesheim, A, Burk, RD, et al. . A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001; 183: 815.
Ho, GY, Studentsov, Y, Hall, CB, et al. . Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 2002; 186: 737742.
Thomas, KK, Hughes, JP, Kuypers, JM, et al. . Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000; 182: 10971102.
Luostarinen, T. No excess risk of cervical carcinoma among women seropostiive for both HPV-16 and HPV6/11. Int J Cancer 1999; 80: 818822.
Lipsitch, M. Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci USA 1997; 94: 65716576.
Garnett, GP, Waddell, HC. Public health paradoxes and the epidemiological impact of an HPV vaccine. J Clin Virol 2000; 19: 101111.
Hughes, JP, Garnett, GP, Koutsky, L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002; 13: 631639.
Goldie, SJ, Grima, D, Kohli, M, Wright, TC, Weinstein, M, Franco, E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003; 106: 896904.
Sasieni, PD, Cuzick, J, Lynch-Farmery, E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. Br J Cancer 1996; 73: 10011005.
Kulasingam, SL, Myers, ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. J Am Med Assoc 2003; 290: 781789.
Whittle, H, Jaffar, S, Wansbrough, M, et al. . Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002; 325: 569.
Stone, KM, Karem, KL, Sternberg, MR, et al. . Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 2002; 186: 13961402.
Winer, RL, Lee, SK, Hughes, JP, Adam, DE, Kiviat, NB, Koutsky, LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157: 218226.
Taira, AV. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10: 19151923.
Stanberry, LR, Spruance, SL, Cunningham, AL, et al. .; GlaxoSmithKline Herpes Vaccine Efficacy Study Group. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347: 16521661.
Waller, J, McCaffery, K, Nazroo, J, Wardle, J. Making sense of information about HPV in cervical screening: a qualitative study. Br J Cancer 2005; 92: 265270.
Rose, RC, White, WI, Li, M, Suzich, JA, Lane, C, Garcea, RL. Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol 1998; 72: 61516154.
Gerber, S, Lane, C, Brown, DM, et al. . Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J Virol 2001; 75: 47524760.

Vaccines for cervical cancer

  • C. M. LOWNDES (a1)

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed